Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency with and without anaemia
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Heart failure; Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms The FAIR-HFpEF Trial
- 09 Feb 2023 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
- 02 Aug 2022 According to a CSL Vifor media release, Vifor Pharma has been acquired by CSL and renamed to CSL Vifor.
- 09 Jun 2017 New trial record